摘要
人参多肽(GP)无论sc或iv(50～200 mg/kg)对大鼠和小鼠均有明显的降低血糖和肝糖原作用,肾上腺切除并未影响其降低肝糖原作用。酚妥拉明和普萘洛尔分別抑制GP对大鼠肝糖原和血糖的影响。GP在降低血糖和肝糖原时,可使小鼠肝组织cAMP增加。由于血及肝组织LDH受到抑制,血乳酸含量降低,而血丙酮酸含量升高。实验证明,GP降血糖作用除了其促进糖原分解或抑制乳酸合成肝糖原作用外,主要由于其刺激了SDH和CCD的活性使糖的有氧氧化作用增强的缘故。
When ginseng polypeptide (GP) Was administered iv or sc to mice or rats, the blood sugar and liver glycogen were decreased. The decrease of blood sugar and liver glycogen induced by GP in rats were inhibited by pretreatments with pentolamine and propranolol, respectively. The results Suggest that the effect of GP on glucose metabolism may be related to adrenergic receptors. In addition, GP at doses which cause decreases of blood sugar and glycogen, inhibited LDH activity, and consequently produced decrease of lactic acid and increase of pyruvic acid. GP was also found to stimulate SDH and CCO activities (which are respiratory enzymes in the electron transport chain), consequently promote earobic oxidation course.
出处
《药学学报》
CAS
CSCD
北大核心
1990年第10期727-731,共5页
Acta Pharmaceutica Sinica
关键词
人参多肽
血糖
肝糖原
Ginseng polypeptide(GP)
Blood sugar
Liver glycogen
Pentolamine
Propranolol
